Conducting Phase II/III study of rhGM-CSF in patients with novel coronavirus infection (COVID-19).

  • Funded by Japan Agency for Medical Research and Development (AMED)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2020
  • Funder

    Japan Agency for Medical Research and Development (AMED)
  • Principle Investigator

    Pending
  • Research Location

    Japan, Western Pacific
  • Lead Research Institution

    Research & Development, Nobelpharma Co Ltd.
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 0 clinical trial

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract